241 related articles for article (PubMed ID: 30878303)
1. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
Bratt O; Holmberg E; Andrén O; Carlsson S; Drevin L; Johansson E; Josefsson A; Nyberg M; Sandberg J; Stattin P; Robinsson D
Eur Urol; 2019 Oct; 76(4):461-466. PubMed ID: 30878303
[TBL] [Abstract][Full Text] [Related]
2. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
[TBL] [Abstract][Full Text] [Related]
3. A randomised trial comparing two protocols for transrectal prostate repeat biopsy: six lateral posterior plus six anterior cores versus a standard posterior 12-core biopsy.
Örtegren J; Holmberg JT; Lekås E; Mana S; Mårtensson S; Richthoff J; Sundqvist P; Kjölhede H; Bratt O; Liedberg F
Scand J Urol; 2019 Aug; 53(4):217-221. PubMed ID: 31204873
[No Abstract] [Full Text] [Related]
4. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
5. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
[TBL] [Abstract][Full Text] [Related]
7. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
[TBL] [Abstract][Full Text] [Related]
8. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
9. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
11. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
[TBL] [Abstract][Full Text] [Related]
12. Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate.
Seles M; Gutschi T; Mayrhofer K; Fischereder K; Ehrlich G; Gallé G; Gutschi S; Pachernegg O; Pummer K; Augustin H
BJU Int; 2016 Apr; 117(4):592-7. PubMed ID: 25726856
[TBL] [Abstract][Full Text] [Related]
13. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
[TBL] [Abstract][Full Text] [Related]
14. Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance.
Merrick GS; Delatore A; Butler WM; Bennett A; Fiano R; Anderson R; Adamovich E
Am J Clin Oncol; 2017 Feb; 40(1):53-59. PubMed ID: 25068472
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Prostate HistoScanning as a Method for Targeted Biopsy in Routine Practice.
Glybochko PV; Alyaev YG; Amosov AV; Krupinov GE; Nir D; Winkler M; Ganzha TM
Eur Urol Focus; 2019 Mar; 5(2):179-185. PubMed ID: 28753891
[TBL] [Abstract][Full Text] [Related]
16. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
17. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
[TBL] [Abstract][Full Text] [Related]
18. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance.
Shapiro DD; Gregg JR; Lim AH; Nogueras-González GM; Choi H; Kang HC; Inguillo IA; Chapin BF; Davis JW; Ward JF
BJU Int; 2021 Mar; 127(3):340-348. PubMed ID: 32357283
[TBL] [Abstract][Full Text] [Related]
19. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
[TBL] [Abstract][Full Text] [Related]
20. Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer.
Barzell WE; Melamed MR; Cathcart P; Moore CM; Ahmed HU; Emberton M
J Urol; 2012 Sep; 188(3):762-7. PubMed ID: 22818143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
